Concepedia

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

Serafín Morales, Antonio Lorenzo, Manuel Ramos, P. Ballesteros, Miguel Méndez, Concepción Almanza, Javier Castellanos, José Andrés Moreno-Nogueira, J. Casal, J. Lizón,

Cancer Chemotherapy and Pharmacology · 2003 · 23 citations · 26 references

DOI

Concepts

References

26

Cancer statistics, 1999

Sarah Landis, Thomas S. Murray, S. Bolden et al. · CA A Cancer Journal for Clinicians · 1999 · 3.1K citations · Full text

One-Sample Multiple Testing Procedure for Phase II Clinical Trials

Thomas R. Fleming · Biometrics · 1982 · 993 citations

, , +17

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Stephen Chan, Kay Friedrichs, D. Noel et al. · Journal of Clinical Oncology · 1999 · 638 citations

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

Luca Gianni, Elisabetta Munzone, Giuseppe Capri et al. · Journal of Clinical Oncology · 1995 · 558 citations

Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy

Jean‐Marc Nabholtz, H.-J. Senn, W.R. Bezwoda et al. · Journal of Clinical Oncology · 1999 · 506 citations